Mitoxantrone is a type of medicine used to treat certain types of cancer. It works by stopping the growth of cancer cells. It is given as an injection, usually into a vein.
Every report comes from a Lived member, sent anonymously.
Have you tried Mitoxantrone for AML (Acute Myeloid Leukemia)?
Mitoxantrone is a chemotherapy medicine given by infusion into a vein. It was once sold as Novantrone, a brand that has been discontinued in the US; it is now available as a generic injection. It has three approved uses that are quite different from one another. In multiple sclerosis (MS), it is approved to reduce relapses and slow the buildup of disability in adults whose disease is getting worse: secondary progressive MS, progressive relapsing MS, and relapsing-remitting MS in which people are not recovering fully between relapses. It is not approved for primary progressive MS, the form that worsens steadily from the start. Because of its serious long-term risks and the many newer MS treatments now available, it is generally reserved for people with active, worsening disease after a careful weighing of benefits and risks. In advanced prostate cancer that no longer responds to hormone treatment, mitoxantrone is given together with a corticosteroid such as prednisone to ease cancer-related pain. In adults with acute myeloid leukemia (called acute nonlymphocytic leukemia on the label), it is combined with another chemotherapy drug, cytarabine, as the first round of treatment.
Mitoxantrone belongs to a group of drugs called anthracenediones, which are closely related to the anthracycline chemotherapy drugs such as doxorubicin. It slips between the strands of DNA and blocks topoisomerase II, an enzyme cells need to untangle and repair their DNA. Cells that cannot manage their DNA properly stop dividing and die, which is how it attacks cancer cells. In MS, the immune system mistakenly damages the protective coating around nerves in the brain and spinal cord. Mitoxantrone suppresses the immune cells involved, including B cells, T cells and macrophages, reducing the inflammation that drives relapses and new damage. The same effect on rapidly dividing cells explains its main side effects: it also lowers healthy blood cell production, and it can injure heart muscle.
Mitoxantrone is always given in a clinic or hospital as an intravenous infusion, usually lasting several minutes to about a quarter of an hour. Doses are calculated from body size (milligrams per square meter of body surface), and the schedule depends on the condition. For MS, it is usually given once every three months. There is a firm lifetime limit on the total amount a person with MS can receive (140 mg per square meter), because heart damage becomes more likely as the total dose adds up. At the usual MS dose, that works out to a little under three years of treatment. For prostate cancer, it is typically given every three weeks alongside a daily corticosteroid. For leukemia, it is given daily for two or three days in hospital as part of a combination course. Before each dose, the care team checks blood counts and liver tests, and for MS, a heart test and, for anyone who could become pregnant, a pregnancy test. A dose may be delayed or stopped based on these results.
In MS studies, the most common side effects were nausea, mild hair thinning, changes to menstrual periods (including periods stopping), mouth sores and more frequent infections such as urinary tract infections and colds. Most were mild to moderate. Urine often turns blue-green, and the whites of the eyes may look bluish, for about a day after each infusion; this is harmless and expected. Mitoxantrone lowers the number of blood cells the bone marrow makes, which reduces the body's ability to fight infection and to clot. Fever, chills, repeated infections, or unusual bruising or bleeding should be reported to the care team right away. At leukemia doses this drop in blood counts is severe and expected, and is managed in hospital. The drug can badly damage skin and tissue if it leaks out of the vein during the infusion. Redness, swelling, pain, burning or a bluish color around the infusion site, during or after the infusion, should be reported to the care team right away. Shortness of breath, swelling of the ankles or feet, sudden weight gain, or a fast or pounding heartbeat can be signs of heart failure. Call the doctor or get medical help right away if these appear, whether during treatment or after it has ended.
Mitoxantrone carries FDA boxed warnings, the most serious level of warning, for two long-term risks. The first is heart failure, which can be fatal and can develop during treatment or months to years after it ends, even in people who have never had heart problems. The risk rises with the total dose received and is higher in people with existing heart disease, previous radiation to the chest, or earlier treatment with anthracycline drugs such as doxorubicin or daunorubicin. Before treatment, everyone has an echocardiogram or similar scan to measure ejection fraction, the share of blood the heart's main pumping chamber pushes out with each beat. People with MS are not treated if this is already below normal, are retested before every dose, stop treatment if it drops meaningfully, and continue yearly heart checks after their last dose. The second is leukemia caused by the treatment itself (secondary acute myeloid leukemia). In a five-year safety study of people with MS, it developed in about 0.6% (3 in 509), and published MS groups report roughly 0.25% to 2.8%. Persistent tiredness, unexplained bruising or bleeding, repeated infections, fever or bone pain after treatment are worth raising promptly. Mitoxantrone may harm a developing baby. People with MS who could become pregnant need a pregnancy test with known results before every dose, even when using birth control, and should use effective contraception. The drug passes into breast milk for weeks, so breastfeeding must stop before treatment. People with MS who have liver problems should generally not receive it, because the liver clears the drug. Few drug interactions have been identified, but the care team should know about any other cancer treatment or heart medicine. The injection also contains a sulfite preservative that can cause allergic-type reactions, which are more common in people with asthma.
Each visit involves checks before the infusion (blood tests, and for MS a heart scan and possibly a pregnancy test), then a short infusion. Nausea and tiredness are common after an infusion, and many people notice the blue-green urine. In MS, trials over two years showed fewer relapses and slower worsening of disability, though the benefit was partial and the studies were small. Because of the lifetime dose limit, mitoxantrone is a time-limited treatment rather than a long-term one, and the care team will plan which MS treatment follows it. Yearly heart monitoring continues after the last dose, and it is worth staying alert to signs of a blood disorder for several years. In advanced prostate cancer, the goal is pain relief and slowing the cancer. In trials it delayed progression by a couple of months on average but did not clearly lengthen survival. In leukemia, it is part of an intensive hospital-based course aimed at remission, with blood counts and infection risk watched closely until the bone marrow recovers.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Mitoxantrone, what you've noticed, or ask the community a question.